Compare ISPC & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISPC | PRFX |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | Israel |
| Employees | N/A | 6 |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9M | 1.6M |
| IPO Year | 2020 | 2020 |
| Metric | ISPC | PRFX |
|---|---|---|
| Price | $0.15 | $2.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 9.3M | 23.0K |
| Earning Date | 04-13-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,291,115.00 | N/A |
| Revenue This Year | $35.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.14 | $0.58 |
| 52 Week High | $2.16 | $3.71 |
| Indicator | ISPC | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 38.81 |
| Support Level | N/A | $1.28 |
| Resistance Level | $0.44 | $2.11 |
| Average True Range (ATR) | 0.04 | 0.23 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 1.94 | 0.00 |
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasise reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the Company's lead product, is based on the local anaesthetic ropivacaine and targets the postoperative pain relief market.